PARP6 Antibody

Research Applications of PARP6 Antibody

PARP6 antibodies are primarily used in:

• Western blotting: To detect PARP6 expression levels in cell lysates (e.g., validating knockout mice models) .

• Immunohistochemistry (IHC): Assessing PARP6 expression in cancer tissues, where positivity correlates with better prognosis in CRC .

• Immunoprecipitation (IP): Studying PARP6’s enzymatic activity via auto-MARylation assays .

Table 1: PARP6 Antibody Performance in Key Studies

Key Research Findings Using PARP6 Antibody

• Tumor suppression: PARP6 inhibits CRC progression by downregulating Survivin, Cyclin B, and Aurora-B while upregulating p21/p27 . Loss of PARP6 correlates with poor prognosis .

• Neuronal function: PARP6 regulates dendritic complexity in hippocampal neurons; catalytically inactive mutants (e.g., C563R) reduce dendritic branching .

• Mutation analysis: The R485H mutation increases dendritic complexity, suggesting gain-of-function activity .

Challenges in PARP6 Antibody Validation

Commercial PARP6 antibodies often lack reliability, as demonstrated by:

• Failure to detect N-terminal regions, limiting comprehensive analysis .

• Inconsistent performance in Western blotting and IHC, necessitating custom-generated antibodies .

Clinical and Therapeutic Implications

• Biomarker potential: PARP6 expression inversely correlates with Ki-67 proliferation index in CRC, making it a prognostic marker .

• Therapeutic targeting: PARP6’s catalytic domain is a focus for developing selective inhibitors, particularly in cancers with PARP6 loss .

Future Directions

• Develop antibodies targeting both N- and C-terminal regions for full functional studies.

• Explore PARP6’s role in other cancers and neurological disorders using validated antibodies.